A5092534502- SARS-CoV-2 and COVID-19 Research
- Animal Virus Infections Studies
- Immunotherapy and Immune Responses
- Bacterial Infections and Vaccines
- SARS-CoV-2 detection and testing
- Viral gastroenteritis research and epidemiology
- COVID-19 Clinical Research Studies
- Respiratory viral infections research
- T-cell and B-cell Immunology
- Monoclonal and Polyclonal Antibodies Research
- Cytomegalovirus and herpesvirus research
Friedrich-Loeffler-Institut
2024
Karolinska University Hospital
2023
Karolinska Institutet
2023
Nanoparticles for multivalent display and delivery of vaccine antigens have emerged as a promising avenue enhancing B cell responses to protein subunit vaccines. Here, we evaluated in rhesus macaques immunized with prefusion-stabilized respiratory syncytial virus (RSV) F glycoprotein trimer compared nanoparticles displaying 10 or 20 copies the same antigen. We show that skews antibody specificities drives epitope-focusing responding cells. Antibody cloning repertoire sequencing revealed...
Approved vaccines are effective against severe COVID-19, but broader immunity is needed new variants and transmission. Therefore, we developed genome-modified live-attenuated (LAV) by recoding the SARS-CoV-2 genome, including 'one-to-stop' (OTS) codons, disabling Nsp1 translational repression removing ORF6, 7ab 8 to boost host immune responses, as well spike polybasic cleavage site optimize safety profile. The resulting OTS-modified LAVs, designated OTS-206 OTS-228, genetically stable can be...
Coronavirus disease 2019 (COVID-19) mRNA vaccines that have contributed to controlling the SARS-CoV-2 pandemic induce specific serum antibodies, which correlate with protection. However, neutralizing capacity of antibodies for emerging variants is altered. Suboptimal antibody responses are observed in patients humoral immunodeficiency diseases, ongoing B cell depletion therapy, and aging. Common experimental mouse models altered compartments, such as or deficiency, do not fully recapitulate...
Vaccines have played a central role in combating the COVID-19 pandemic, but newly emerging SARS-CoV-2 variants are increasingly evading first-generation vaccine protection. To address this challenge, we designed "single-cycle infection viruses" (SCVs) that lack essential viral genes, possess distinctive immune-modulatory features, and exhibit an excellent safety profile Syrian hamster model. Animals intranasally vaccinated with Envelope-gene-deleted candidate were fully protected against...